Cannabis: CBD vs THC causes lower psychiatric side-effects

A new study published in the Journal of Neuroscience demonstrates how cannabidiol (CBD) works against tetrahydrocannabinol (THC), which is the principal psychedelic component of cannabis, to prevent its psychiatric side effects. They explored the role played by a molecule called extracellular signal-regulated kinase (ERK) in the brain hippocampus, and found it was responsible for the psychological effects of THC.

cbd-cannabisHQuality | Shutterstock

Earlier research has shown that cannabis plants with higher levels of THC and lower levels of CBD have a greater tendency to produce paranoia and other psychiatric side effects, as well as to induce anxiety and addiction. These two compounds, called phytocannabinoids, act differently to modulate the brain response to environmental stimuli that promise a reward (called ‘cues’). This is called salience, and describes how a given cue is different or outstanding compared to surrounding cues. Salient cues are relevant and evoke appropriate attention in normal people. When the individual abuses drugs, the brain gives greater attention to cues that evoke the drug of abuse, giving them the status of a motivational incentive. In psychotic individuals, useless stimuli are invested with great salience and thus attract greater attention and motivate behavior inappropriately.

The association of relevance with emotional states is regulated by the ventral hippocampus through dopamine-releasing neurons. The activity of these neurons is poorly or wrongly controlled in individuals with psychotic behavior.

What the researchers did

To find out more about how this works, the study fed rats with different cannabinoid compounds. Those who were given THC showed a higher concentration of ERK in the hippocampus of the brain, displayed more anxious behavior, and were quicker to learn skills in response to fear (fear-based learning). This was accompanied by faster and stronger dopamine release by neurons in the hippocampal region, slower release of the inhibitory nerve transmitter GABA, and increased brainwave activity in response to ERK modulation. These responses closely resemble symptoms of psychosis.

However, when the rats were given both CBD and THC, they showed normalized levels of ERK, were less anxious and did not respond readily to learning programs based on fear. CBD in the presence of THC reduced ERK signaling. This was proved by giving the rats a drug that reactivated ERK. This led to a reversal of inhibition by CBD.

The researchers arrived at the conclusion that CBD possibly blocks the THC-mediated ERK phosphorylation, inhibiting the ERK signaling in the hippocampus that causes psychosis-like effects. This inhibition prevents the hyperstimulation of this area in response to THC.

Implications of the study

The study thus identifies, at molecular levels, a currently unknown mode by which CBD interferes with brain processes. The implications of the study are obvious. For people who are vulnerable to develop psychotic-like symptoms with cannabis but require this drug for therapeutic indications, the key is to use cannabis from plants that have high CBD and low THC levels. Another useful avenue is producing safer TCH formulations with higher efficacy on the basis of this discovery.

CBD by itself had no effect. However, by co-administering CBD and THC, we completely reversed the direction of the change on a molecular level. CBD was also able to reverse the anxiety-like behaviour and addictive-like behaviour caused by the THC.”

Researcher Roger Hudson

The team will, therefore, look deeper into how this mechanism works, and how to make therapeutic preparations that produce more THC with minimal adverse reactions, and also make better formulations based on CBD.

Journal reference:

Cannabidiol counteracts the psychotropic side-effects of δ-9-tetrahydrocannabinol in the ventral hippocampus through bi-directional control of ERK1-2 phosphorylation. Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette. Journal of Neuroscience. 30 September 2019, 0708-19; DOI: https://www.jneurosci.org/content/early/2019/09/27/JNEUROSCI.0708-19.2019

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2019, October 01). Cannabis: CBD vs THC causes lower psychiatric side-effects. News-Medical. Retrieved on December 15, 2019 from https://www.news-medical.net/news/20191001/Cannabis-CBD-vs-THC-causes-lower-psychiatric-side-effects.aspx.

  • MLA

    Thomas, Liji. "Cannabis: CBD vs THC causes lower psychiatric side-effects". News-Medical. 15 December 2019. <https://www.news-medical.net/news/20191001/Cannabis-CBD-vs-THC-causes-lower-psychiatric-side-effects.aspx>.

  • Chicago

    Thomas, Liji. "Cannabis: CBD vs THC causes lower psychiatric side-effects". News-Medical. https://www.news-medical.net/news/20191001/Cannabis-CBD-vs-THC-causes-lower-psychiatric-side-effects.aspx. (accessed December 15, 2019).

  • Harvard

    Thomas, Liji. 2019. Cannabis: CBD vs THC causes lower psychiatric side-effects. News-Medical, viewed 15 December 2019, https://www.news-medical.net/news/20191001/Cannabis-CBD-vs-THC-causes-lower-psychiatric-side-effects.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Number of children requiring treatment for cannabis misuse failed to improve in the last 3 years